Agile Therapeutics (AGRX) recently announced that the FDA decided to extend Twirla’s PDUFA goal date from November 16th to February 16th, 2020. This extension comes about a week after Twirla received a positive vote in support of approval from the FDA’s Bone, Reproductive, and Urologic Drugs Advisory Committee “BRUDAC.” Following the press release, the share price was nearly cut in half, which I believe is an opportunity for investors who have been waiting for an entry point or are looking to add to their position.
I will provide some background information